Z

    Zentalis Pharmaceuticals Llc (ZNTL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.76
    -0.04 (-1.05%)

    Market Cap: $359.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(11/26)
    Avg Surprise
    -17.38%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.58
    Range$-0.66 - $-0.50
    7 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.44+23.2%
    60d ago$-0.49+15.6%
    30d ago$-0.49+15.6%
    7d ago$-0.49+15.1%
    Current$-0.58
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.53
    Range$-0.81 - $0.21
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.53---
    Sep 26EST
    		-$-0.58---
    Jun 26
    		$-0.59$-0.45-31.11%Miss-59.5%
    Mar 26
    		$-0.50$-0.47-7.43%Miss+24.9%
    Dec 25
    		$-0.49$-0.61+19.67%Beat+20.2%
    Sep 25
    		$-0.37$-0.48+22.92%Beat+33.9%
    Jun 25
    		$-0.37$-0.52+28.85%Beat+70.2%
    Mar 25
    		$-0.67$-0.61-9.84%Miss-578.6%
    Dec 24
    		$-0.61$-0.68+9.96%Beat+34.0%
    Sep 24
    		$-0.56$-0.87+35.63%Beat+29.1%
    Jun 24
    		$-1.24$-0.83-49.40%Miss+33.0%
    Mar 24
    		$0.14N/A+118.92%Beat+113.1%
    Dec 23
    		$-0.93$-0.92-1.09%Miss-1.1%
    Sep 23
    		$-0.79$-0.94+15.96%Beat+17.7%
    Jun 23
    		$-1.85$-1.02-81.37%Miss-38.1%
    Mar 23
    		$-1.07$-1.03-3.88%Miss+18.3%
    Dec 22
    		$-0.92$-1.06+13.21%Beat+17.1%
    Sep 22
    		$-0.96$-1.19+19.33%Beat-966.7%
    Jun 22
    		$-1.34$-1.20-11.67%Miss+0.0%
    Mar 22
    		$-1.31$-1.20-9.17%Miss-5.6%
    Dec 21
    		$-1.11$-1.49+25.50%Beat-9.9%
    Sep 21
    		$-0.09N/A+92.80%Beat+90.1%
    Jun 21
    		$-1.34$-1.16-15.52%Miss-71.8%
    Mar 21
    		$-1.24$-0.91-36.26%Miss+56.9%
    Dec 20
    		$-1.01$-0.95-6.32%Miss-
    Sep 20
    		$-0.91$-0.76-19.74%Miss-
    Jun 20
    		$-0.78$-0.49-59.18%Miss-
    Mar 20
    		$-2.88$-0.47-512.77%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.93EV/EBITDA-2.31x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-66.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.82xQuick Ratio4.82x
    Trading Statistics
    Beta1.89Avg Volume1.07M
    52-Week High$6.9552-Week Low$1.21

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.81
    SMA 20$4.06
    SMA 50$4.36
    SMA 200$3.20
    EMA 10$3.86
    EMA 20$4.01
    EMA 50$4.15
    EMA 200$3.42

    MACD

    Line: -0.18Signal: -0.17Hist: -0.01

    ADX

    ADX: 19.2+DI: 16.5-DI: 27.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down56.0
    PSAR$4.48

    Bollinger Bands

    Upper Band$4.91
    Lower Band$3.20
    %B Position4212%(Upper)
    Band Width0.33

    RSI (14-Day)

    Neutral
    40.0

    Momentum Oscillators

    Stoch %K34.8
    Stoch %D33.9
    Williams %R-71.0
    ROC (10d)1.5%
    Momentum0.06
    CCI (20d)-65.8
    MFI (14d)54.1

    Volatility Measures

    ATR (14d)$0.27(7.2%)
    StdDev (20d)0.43
    Hist Vol84.7%(High)

    Volume Flow

    VWAP$3.74
    OBV74.9M
    AD Line50.1M
    CMF (20d)-0.099

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.4x(Low)
    VWMA (20d)$3.93

    Pivot Points

    R3$4.06
    R2$3.97
    R1$3.89
    Pivot Point$3.80
    S1$3.72
    S2$3.63
    S3$3.55

    Advanced Oscillators

    TSI-17.02
    Ultimate Osc42.1
    KST-172.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26.86M$0$0$40.56M$2.10M$0
    Cost of Revenue$0$0$157,000$0$0$0$317,000$0$0$0$337,000$0
    Gross Profit$0$0$-157,000$0$0$0$26.86M$0$0$40.56M$1.77M$0
    Operating Expenses$44.39M$37.85M$37.39M$33.73M$36.06M$45.62M$76.71M$51.43M$65.15M$65.33M$67.92M$62.72M
    R&D$35.16M$28.72M$29.49M$22.95M$27.61M$27.25M$32.97M$36.82M$48.39M$49.59M$51.56M$46.77M
    SG&A$9.23M$9.14M$7.91M$10.78M$8.45M$10.58M$40.01M$14.61M$16.76M$15.74M$16.36M$15.95M
    Operating Income$-44,391,000$-37,855,000$-37,393,000$-33,734,000$-36,058,000$-45,623,000$-49,849,000$-51,432,000$-65,148,000$-24,765,000$-67,922,000$-62,718,000
    Interest Income$2.24M$0$0$0$0$-2,656,000$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$2.66M$0$0$22.86M$0$0$0
    Income Before Tax$-42,148,000$-35,232,000$-34,774,000$-26,691,000$-26,874,000$-48,279,000$-47,677,000$-40,185,000$-88,011,000$10.18M$-61,074,000$-55,509,000
    Income Tax Expense$138,000$120,000$442,000$0$0$0$-205,000$-27,000$266,000$143,000$-135,000$31,000
    Net Income$-42,286,000$-35,352,000$-35,216,000$-26,691,000$-26,874,000$-48,279,000$-47,472,000$-40,158,000$-88,277,000$10.04M$-60,939,000$-55,540,000
    EBITDA$-44,287,000$-35,305,000$-35,048,000$-27,048,000$-27,495,000$-46,395,000$-48,757,000$-41,509,000$-89,880,000$7.74M$-65,292,000$-57,280,000
    EBIT$-44,391,000$-35,232,000$-34,774,000$-26,691,000$-26,874,000$-45,623,000$-47,677,000$-40,185,000$-88,011,000$10.18M$-61,074,000$-55,509,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ZNTL

    News

    Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock

    A 10% shareholder of Zentalis Pharmaceuticals (ZNTL.US) recently purchased $15.17 million worth of the company's common stock. This significant insider transaction indicates confidence in the company's future prospects.

    Moomoo•8/20/26•
    Bullish

    Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

    Major shareholder Group Walters purchased 4,335,000 shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock for $15.17 million, increasing their position by 32.09% to 17.84 million shares. This transaction occurred on August 14th, with the stock bought at an average price of $3.50 per share. Despite the insider buying, Zentalis Pharmaceuticals recently reported a quarterly loss of $0.59 per share, missing analyst estimates, and shares traded up 3.8% to $3.82.

    MarketBeat•8/19/26•
    Somewhat-Bearish

    Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group

    An amended Schedule 13G/A filing reveals that The Walters Group, associated with William T. Walters and Susan B. Walters, holds 18.8% of Zentalis Pharmaceuticals (NASDAQ: ZNTL) common stock. This significant ownership amounts to 17,844,973 shares out of 94,668,568 shares outstanding. The group reports shared voting and dispositive power over these shares, indicating a collective influence on the company.

    Stock Titan•8/19/26•
    Neutral

    Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock

    Walters Group, a 10% owner and director of Zentalis Pharmaceuticals Inc., acquired 4,335,000 shares of the company's common stock for $15.17 million at $3.50 per share. This transaction increases their total beneficial ownership to 17,844,973 shares, despite a recent decline in the stock, which has seen a 140% return over the last year. The acquisition comes amidst other company news including a public stock offering, positive analyst coverage for its drug candidate azenosertib, and new board appointments.

    Investing.com•8/19/26•
    Neutral

    Zentalis Pharmaceuticals closes $92.6 million stock offering

    Zentalis Pharmaceuticals Inc. has successfully closed an underwritten public offering of 26,450,000 shares of common stock at $3.50 per share, raising approximately $92.6 million in gross proceeds. The company plans to utilize these net proceeds, along with existing funds, to advance clinical trials, preclinical studies, regulatory filings, manufacturing, and its companion diagnostic program for azenosertib, a WEE1 inhibitor in late-stage development. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. served as joint bookrunners for the offering.

    Investing.com•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About ZNTL

    Does ZNTL pay dividends?
    Zentalis Pharmaceuticals Llc (ZNTL) does not currently pay a regular dividend.
    What is ZNTL's market cap?
    Zentalis Pharmaceuticals Llc (ZNTL) has a market capitalization of $359.75M with a current stock price of $3.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In